A cure for this disease would change the lives of so many.
We need laws in place that will allow all patients, regardless of background, to have access to life-saving medication.
Taxpayer-Funded Drugs and a Pricing Crisis: A Cure for Sickle Cell
American Taxpayers invested hundreds of millions of dollars into a gene therapy to cure sickle cell disease; now a drug company is likely to make billions and price it out of reach.
10 Drug Corporations Drive One-Third of Taxpayer Spending in Medicare Part D
New data show how negotiating for the 250 most-expensive drugs could save patients, taxpayers billions.
Insulin affordability is a crisis.
I have to find innovative ways to gain access to the drugs I need just to survive. I ration my medication and buy expired or leftover insulin.
2,879 Medicare Part D Drugs Total $151 Billion in Spending
P4AD Analysis of 2017 Medicare Part D Spending
Vertex is pricing life-saving medicines out of reach.
If the children for whom these medicines are created continue to suffer and die, it’s as if the drugs were never made at all.
CHART PACK: New Analysis Shows Lion’s Share Of Part D Spending is For a Small Percentage of Drugs
The analysis, using data from CMS’ Medicare Part D Drug Spending Dashboard, shows that less than 1 percent of drugs accounts for 17 percent of spending and 3.5 percent account for nearly 60 percent of spending.
$2.1 Million Drug Marks Troubling Trend in Drug Pricing
The question in drug pricing isn’t how much is a life worth; it’s what makes a fair return on an investment in R&D and an accessible price.
